2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Solventum company profile · wound care, dental and health information systems · history · financial snapshot · S&P 500 rank #450 · Solventum公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | SOLV (NYSE) |
| Company | Solventum Corporation |
| GICS sector / industry | Health Care / Health Care Technology |
| S&P 500 rank (by weight) | #450 · 0.02% (Nov 4, 2026) |
| Sector rank (by S&P 500 weight) | #52 in Health Care (Nov 4, 2026) |
| Headquarters | Maplewood, Minnesota |
| Founded | 2024, spun off from 3M (separation completed April 1, 2024); previously part of 3M’s Health Care business |
| CEO | Bryan Hanson (president & CEO) |
| Employees | ≈20,000 employees (FY2025 10-K) |
| Market cap | $14.43B (Nov 4, 2026) |
| SEC filings | EDGAR — CIK 0001964738 |
WHAT IT DOES
Solventum is a healthcare company separated from 3M on April 1, 2024. It reports three segments: MedSurg (negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, IV site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, electrodes and OEM technologies); Dental Solutions (brackets, aligners, restorative cements and bonding agents spanning prevention, restoration, replacement and malocclusion); and Health Information Systems (computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition and data visualization, designed to eliminate revenue-cycle waste and support value-based care).
FY2025 was the company’s first full calendar year as a standalone company. Net sales were $8.33B, up 0.9%, and net income was $1.56B, or $8.88 per diluted share, against $479M, or $2.76, in 2024. That comparison is not a clean trend measure: 2025 includes the gain on the sale of Purification and Filtration (completed September 1, 2025) inside Corporate and Unallocated, and 2024 comparatives straddle the spin-off. Adjusted diluted EPS (non-GAAP) was $6.11, down 8.8% from $6.70. The 10-K itself warns that historical pre-spin financial information is carve-out information and is not necessarily representative of standalone results — pre-spin standalone figures are therefore not presented as standalone comparables in this profile.
Purification and Filtration, sold on September 1, 2025 under an agreement dated February 25, 2025, contributed $497M of net sales in FY2025, covering only the pre-sale period. The retained Water Business, previously part of Purification and Filtration, is reported in All Other together with sales under 3M supply agreements. In December 2025 Solventum acquired Acera as a wholly owned subsidiary; total assets and net sales of the acquired business were each under 1% of consolidated amounts at December 31, 2025.
SEGMENTS — FY2025 NET SALES
| Segment | Net sales | Share | YoY |
|---|---|---|---|
| MedSurg | $4.82B | 57.9% | +3.9% |
| Dental Solutions | $1.35B | 16.2% | +4.2% |
| Health Information Systems | $1.36B | 16.3% | +4.1% |
| Purification and Filtration | $0.50B | 6.0% | −29.9% |
| All Other | $0.30B | 3.6% | −1.3% |
HISTORY
| Year | Milestone |
|---|---|
| Before 2024 | The business operates as 3M’s Health Care business; its historical financial information is carve-out information, not standalone results. |
| 2024 | The separation from 3M is completed on April 1, 2024; Solventum lists on the NYSE as an independent publicly traded company. |
| 2025 | Solventum agrees on February 25, 2025 to sell Purification and Filtration and completes the sale on September 1, 2025; in December 2025 it acquires Acera as a wholly owned subsidiary. |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Net sales | $8.33B |
| Total operating income | $2.18B |
| Income before income taxes | $1.71B |
| Net income | $1.56B |
| Diluted EPS | $8.88 |
| Adjusted diluted EPS (non-GAAP) | $6.11 |
| Net interest expense | $347M |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Solventum is the S&P 500’s newest standalone health-care name: wound-care volumes, dental demand and health-information software adoption read as gauges of hospital spending, dental visits and the shift to value-based care. At rank #450 by weight (0.02%) — Health Care #52 — it is a spin-off still proving its standalone cost structure after its first full year outside 3M.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by weight (rank, weight, price — Nov 4, 2026 crawl) · StockAnalysis (market cap — Nov 4, 2026 crawl, single source) |
| Financials | Form 10-K for FY2025 (year ended Dec 31, 2025), filed Feb 27, 2026 |
| Sector classification | GICS via the List of S&P 500 companies (Wikipedia) |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | SOLV(NYSE) |
| 公司 | Solventum Corporation |
| GICS 板塊/行業 | 醫療保健/Health Care Technology |
| 標普500排名(按權重) | 第450名 · 0.02%(2026 年 11 月 4 日) |
| 板塊內排名(按標普500權重) | 醫療保健第52名(2026 年 11 月 4 日) |
| 總部 | 明尼蘇達州梅普爾伍德 |
| 成立 | 2024年,自 3M 分拆(分拆於2024年4月1日完成);此前為 3M 醫療保健業務 |
| 行政總裁 | Bryan Hanson(總裁兼行政總裁) |
| 員工 | 約20,000名員工(FY2025 10-K) |
| 市值 | $14.43B(2026 年 11 月 4 日) |
| SEC 文件 | EDGAR — CIK 0001964738 |
業務概覽
Solventum 是一家於2024年4月1日自 3M 分拆出來的醫療保健公司。它報告三個板塊:MedSurg(負壓傷口治療、先進傷口敷料、先進皮膚護理、合成組織基質、靜脈置管管理、滅菌保證、體溫管理、外科用品、醫用膠帶及包紮、聽診器、電極及 OEM 技術);牙科解決方案(托槽、矯治器、修復水泥及黏合劑,涵蓋預防、修復、替換及錯頜畸形);以及健康資訊系統(電腦輔助醫生文件記錄、直接計費及編碼自動化、分類方法、語音識別及數據可視化,旨在消除收入週期浪費並支持基於價值的護理)。
FY2025 是公司作為獨立公司的首個完整曆年。淨銷售額為83.3億美元,增長0.9%,淨利潤為15.6億美元,即攤薄每股收益8.88美元,而2024年為4.79億美元,即2.76美元。這一比較並非清晰的趨勢指標:2025年包括於企業及未分配部門內的純化及過濾業務出售收益(於2025年9月1日完成),而2024年比較數字橫跨分拆。經調整攤薄每股收益(非 GAAP)為6.11美元,較6.70美元下跌8.8%。10-K 本身警告,歷史分拆前財務資料為分拆資料,不一定代表獨立公司的業績——因此本介紹不將分拆前數字作為獨立可比數字呈現。
純化及過濾業務根據2025年2月25日的協議,於2025年9月1日出售,於 FY2025 貢獻4.97億美元淨銷售額,僅涵蓋出售前的期間。保留的水務業務(此前屬於純化及過濾)連同 3M 供應協議下的銷售,一併於其他部門報告。2025年12月,Solventum 收購 Acera 作為全資子公司;於2025年12月31日,被收購業務的總資產及淨銷售額各佔綜合金額不足1%。
板塊 — FY2025 淨銷售額
| 板塊 | 淨銷售額 | 佔比 | 同比 |
|---|---|---|---|
| MedSurg | 48.2億美元 | 57.9% | +3.9% |
| 牙科解決方案 | 13.5億美元 | 16.2% | +4.2% |
| 健康資訊系統 | 13.6億美元 | 16.3% | +4.1% |
| 純化及過濾 | 5.0億美元 | 6.0% | −29.9% |
| 其他 | 3.0億美元 | 3.6% | −1.3% |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 2024年之前 | 該業務作為 3M 的醫療保健業務營運;其歷史財務資料為分拆資料,並非獨立業績。 |
| 2024年 | 自 3M 的分拆於2024年4月1日完成;Solventum 以獨立上市公司的身份於紐約證券交易所上市。 |
| 2025年 | Solventum 於2025年2月25日同意出售純化及過濾業務,並於2025年9月1日完成出售;2025年12月收購 Acera 作為全資子公司。 |
競爭地位
財務快照 — FY2025
| 淨銷售額 | 83.3億美元 |
| 總營運利潤 | 21.8億美元 |
| 所得稅前利潤 | 17.1億美元 |
| 淨利潤 | 15.6億美元 |
| 攤薄每股收益 | 8.88美元 |
| 經調整攤薄每股收益(非 GAAP) | 6.11美元 |
| 淨利息支出 | 3.47億美元 |
主要風險
對標普500的重要性
Solventum 是標普500中最新的獨立醫療保健公司:傷口護理量、牙科需求及健康資訊軟件採用情況,可反映醫院開支、牙科就診及向基於價值的護理轉變。按權重排名第450位(0.02%)——醫療保健第52名——它是一家分拆公司,在脫離 3M 後的首個完整年度,仍在證明其獨立成本結構。
來源與方法
| 市場數據 | Slickcharts 標普500權重榜(排名、權重、價格——2026 年 11 月 4 日抓取)· StockAnalysis(市值——2026 年 11 月 4 日抓取,單一來源) |
| 財務 | FY2025 10-K(截至2025年12月31日的年度),2026年2月27日提交 |
| 板塊分類 | GICS,據 S&P 500 公司清單(Wikipedia) |
| 圖庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-04 02:04 · updated 2026-11-15 00:02 · rev 5